newsfilter
← Latest News
Business Wire·

Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

RDY
  • Dr. Reddy's Laboratories launched generic Sugammadex Injection 200 mg/2 mL & 500 mg/5 mL single-dose vials in the US as a generic equivalent of Bridion®.
  • The product launch occurred on the first day of generic availability, highlighting the company's commitment to execution excellence & supply reliability.
  • Sugammadex Injection (100 mg/mL) is indicated for reversing neuromuscular blockade induced by rocuronium bromide & vecuronium bromide in adults & pediatric patients aged 2 years and older undergoing surgery.
  • Bridion® brand sales reached approximately $1.6 billion in the US for the 12-month period ended May 2026 according to IQVIA data.
  • Bridion® is a registered trademark of Merck Sharp & Dohme B.V.
  • Dr. Reddy's is a global pharmaceutical company headquartered in Hyderabad, India, established in 1984, with major markets including the US, India, Russia, China, Brazil, & Europe.
  • The company's therapeutic focus areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management, & dermatology.